Zeltiq Aesthetics Inc  

(Public, NASDAQ:ZLTQ)   Watch this stock  
Find more results for ZLTQ
4.90
-0.24 (-4.67%)
Real-time:   12:07PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.85 - 5.15
52 week 3.85 - 17.41
Open 5.14
Vol / Avg. 43,158.00/136,247.00
Mkt cap 167.86M
P/E     -
Div/yield     -
EPS -0.85
Shares 34.26M
Beta     -
Inst. own 94%
Jul 31, 2012
Q2 2012 ZELTIQ Aesthetics Inc Earnings Conference Call
Jul 31, 2012
Q2 2012 ZELTIQ Aesthetics Inc Earnings Release
Jun 15, 2012
ZELTIQ Aesthetics Inc Annual Shareholder Meeting
Jun 13, 2012
ZELTIQ Aesthetics Inc at William Blair and Co LLC Growth Stock Conference
Jun 5, 2012
ZELTIQ Aesthetics Inc at Goldman Sachs Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '12) 2011
Net profit margin -36.38% -14.09%
Operating margin -36.22% -12.76%
EBITD margin - -11.49%
Return on average assets -33.45% -15.33%
Return on average equity -39.69% -299.74%
Employees 153 -
Carbon Disclosure Rating - -

Address

Suite 100, 4698 Willow Road
PLEASANTON, CA 94588
United States - Map
+1-925-4742500 (Phone)
+1-925-4742599 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

ZELTIQ Aesthetics, Inc. (ZELTIQ) is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product is the CoolSculpting System that reduces stubborn fat bulges. The Company generates revenues from capital sales of its CoolSculpting System and from procedure fees its physician customers pay for each CoolSculpting procedure they perform. As of March 31, 2011, it had an installed base of 346 and 475 CoolSculpting Systems worldwide and over 88,000 CoolSculpting procedures had been sold to its physician customers. The Company markets CoolSculpting to the dermatologists, plastic surgeons, and aesthetic specialists. As of March 31, 2011, ZELTIQ�s North American direct sales force consisted of 23 professionals, and over 88,000 CoolSculpting procedures were sold to ZELTIQ�s physician customers.

Officers and directors

Mark J. Foley Interim President and Chief Executive Officer, Director
Age: 46
Bio & Compensation - Reuters
Joshua T. Brumm Chief Financial Officer, Senior Vice President
Age: 34
Bio & Compensation - Reuters
Michael C. Genau President - North American Franchise
Age: 52
Bio & Compensation - Reuters
Sergio Garcia-Rodriguez Senior Vice President, General Counsel and Corporate Secretary
Age: 50
Bio & Compensation - Reuters
Stephen W. Atkinson Senior Vice President, International
Age: 44
Bio & Compensation - Reuters
Richard W. Poinsett Senior Vice President - Operations
Age: 60
Bio & Compensation - Reuters
Dennis J. Jarvis Ph.D. Chief Marketing Officer
Age: 61
Bio & Compensation - Reuters
Kristine N. Tatsutani Ph.D. Vice President - Enhanced Clinical Outcomes, Chief Technology Officer
Age: 44
Bio & Compensation - Reuters
Jean M. George Independent Director
Age: 54
Bio & Compensation - Reuters
Kevin C. O'Boyle Independent Director
Age: 56
Bio & Compensation - Reuters